Literature DB >> 9564716

Associations between central obesity and indexes of hemostatic, carbohydrate and lipid metabolism. Results of a 1-year intervention from the Oslo Diet and Exercise Study.

S A Anderssen1, I Holme, P Urdal, I Hjermann.   

Abstract

The relationships of central obesity and physical fitness to indexes of hemostatic, lipid and glucose metabolism both at baseline and after 1 year of diet and exercise intervention were examined in 209 sedentary middle-aged men and women with increased coronary risk factor levels. Central obesity was measured as either waist circumference or waist/hip ratio. Maximal oxygen uptake was used as a measure of physical fitness. The cross-sectional results show that there were significant correlations between waist circumference and euglobuline clot lysis time (r = 0.23), factor VII (r = 0.16), glucose and insulin before and after 1 h glucose load (r ranging from 0.32 to 0.50). The 1-year intervention gave the following associations between changes in waist circumference and changes in: euglobuline clot lysis time (r = 0.27), factor VII (r = 0.19), carbohydrate variables and lipids (magnitude of r ranging from 0.19 to 0.43). Also the other indexes of obesity and physical fitness showed significant correlations to indexes of hemostatic, lipid and glucose variables, both cross-sectionally and for changes after the 1-year intervention. The associations between changes in central obesity and changes in indexes of hemostatic, carbohydrate and lipids were generally stronger during 1 year of diet and exercise intervention than those found at baseline. Multiple regression analyses with waist circumference, waist/hip ratio, percent body fat and Vo2 max as independent variables and indexes of hemostatic, carbohydrate and lipid metabolism as dependent variables showed that waist circumference was a significant predictor for indexes of the hemostatic, carbohydrate and lipid metabolism, mostly independent of physical fitness. The cross-sectional and 1-year change results support each other and therefore underscore the importance of abdominal obesity as an important risk factor for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564716     DOI: 10.1111/j.1600-0838.1998.tb00177.x

Source DB:  PubMed          Journal:  Scand J Med Sci Sports        ISSN: 0905-7188            Impact factor:   4.221


  5 in total

1.  Overall obesity and abdominal obesity and the risk of metabolic abnormalities.

Authors:  S W Lai; K C Ng
Journal:  Ir J Med Sci       Date:  2004 Oct-Dec       Impact factor: 1.568

2.  Effects of long-term exercise on plasma adipokine levels and inflammation-related gene expression in subcutaneous adipose tissue in sedentary dysglycaemic, overweight men and sedentary normoglycaemic men of healthy weight.

Authors:  Sindre Lee; Frode Norheim; Torgrim M Langleite; Hanne L Gulseth; Kåre I Birkeland; Christian A Drevon
Journal:  Diabetologia       Date:  2019-04-22       Impact factor: 10.122

Review 3.  What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome.

Authors:  Sean Carroll; Mike Dudfield
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

4.  Arnebia euchroma ointment can reduce abdominal fat thickness and abdominal circumference of overweight women: A randomized controlled study.

Authors:  Mansour Siavash; Mohsen Naseri; Mojgan Rahimi
Journal:  J Res Med Sci       Date:  2016-08-01       Impact factor: 1.852

Review 5.  Effect of lifestyle interventions on cardiovascular risk factors among adults without impaired glucose tolerance or diabetes: A systematic review and meta-analysis.

Authors:  Xuanping Zhang; Heather M Devlin; Bryce Smith; Giuseppina Imperatore; William Thomas; Felipe Lobelo; Mohammed K Ali; Keri Norris; Stephanie Gruss; Barbara Bardenheier; Pyone Cho; Isabel Garcia de Quevedo; Uma Mudaliar; Christopher D Jones; Jeffrey M Durthaler; Jinan Saaddine; Linda S Geiss; Edward W Gregg
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.